Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IRLA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Apilimod Mesylate | COVID-19 Disease | Phase 2 · NCT04446377 | Completed |
| LAM-001 | Bronchiolitis Obliterans Syndrome | Phase 2 · NCT06018766 | Recruiting |
| Apilimod Dimesylate Capsule (LAM-002A) | Amyotrophic Lateral Sclerosis | Phase 2 · NCT05163886 | Completed |
| Open Label LAM-003 | Oncology | Phase 1 · NCT03426605 | Completed |
Also used in these trials (approved or third-party drugs, not IRLA's own candidates): Atezolizumab, Rituximab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IRLA holds $230.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $13.3M/quarter from operations, an estimated runway of 52.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Accordingly, the Company concluded that substantial doubt about the Company’s ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IRLA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| GROUP ONE TRADING LLC | Institution (13G, 5%+) | 5,942,906 | 584.32% | 2026-02-28 |
| Millennium Management LLC | 5%+ holder (13G) | 1,403,697 | 138.01% | 2026-06-04 |
| Dirk Thye CEO and CMO, Director · +2.35M options |
Insider | 994,885 | 97.82% | 2025-12-10 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 912,853 | 89.75% | 2026-10-06 |
| James B. Tananbaum | 5%+ holder (13G) | 652,039 | 64.11% | 2026-10-06 |
| Brendan Hannah CBO, COO & CCO · +1.10M options |
Insider | 361,827 | 35.58% | 2025-12-05 |
| Charles S. Ryan President · +507,548 options |
Insider | 130,009 | 12.78% | 2025-06-18 |
| Cormorant Asset Management, LP | Institution (13G, 5%+) | 108,029 | 10.62% | 2026-06-30 |
| BALYASNY ASSET MANAGEMENT L.P. | Institution (13G, 5%+) | 97,699 | 9.61% | 2026-06-30 |
| Ikarian Capital, LLC | Institution (13G, 5%+) | 91,789 | 9.02% | 2026-06-30 |
| Squadron Master Fund LP | 5%+ holder (13G) | 55,173 | 5.42% | 2026-07-28 |
| Luca Benatti Director · +27,000 options |
Insider | 39,179 | 3.85% | 2025-12-26 |
Share count 1,017,063 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IRLA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →